From the Allergy and Immunology Service, Walter Reed National Military Medical Center, Bethesda, Maryland; and.
Immunization Healthcare Division, Defense Health Agency - Public Health, Falls Church, Virginia.
Allergy Asthma Proc. 2024 Sep 1;45(5):305-309. doi: 10.2500/aap.2024.45.240050.
The complement system is an important component of innate and adaptive immunity that consists of three activation pathways. The classic complement pathway plays a role in humoral immunity, whereas the alternative and lectin pathways augment the innate response. Impairment, deficiency, or overactivation of any of the known 50 complement proteins may lead to increased susceptibility to infection with encapsulated organisms, autoimmunity, hereditary angioedema, or thrombosis, depending on the affected protein. Classic pathway defects result from deficiencies of complement proteins C1q, C1r, C1s, C2, and C4, and typically manifest with features of systemic lupus erythematosus and infections with encapsulated organisms. Alternative pathway defects due to deficiencies of factor B, factor D, and properdin may present with increased susceptibility to Neisseria infections. Lectin pathway defects, including Mannose-binding protein-associated serine protease 2 (MASP2) and ficolin 3, may be asymptomatic or lead to pyogenic infections and autoimmunity. Complement protein C3 is common to all pathways, deficiency of which predisposes patients to severe frequent infections and glomerulonephritis. Deficiencies in factor H and factor I, which regulate the alternative pathway, may lead to hemolytic uremic syndrome. Disseminated Neisseria infections result from terminal pathway defects (i.e., C5, C6, C7, C8, and C9). Diagnosis of complement deficiencies involves screening with functional assays (i.e., total complement activity [CH50], alternative complement pathway activity [AH50], enzyme-linked immunosorbent assay [ELISA]) followed by measurement of individual complement factors by immunoassay. Management of complement deficiencies requires a comprehensive and individualized approach with special attention to vaccination against encapsulated bacteria, consideration of prophylactic antibiotics, treatment of comorbid autoimmunity, and close surveillance.
补体系统是先天和适应性免疫的重要组成部分,由三条激活途径组成。经典补体途径在体液免疫中发挥作用,而替代途径和凝集素途径增强先天反应。任何已知的 50 种补体蛋白的功能障碍、缺乏或过度激活都可能导致对带囊生物体感染、自身免疫、遗传性血管性水肿或血栓形成的易感性增加,具体取决于受影响的蛋白。经典途径缺陷是由于补体蛋白 C1q、C1r、C1s、C2 和 C4 的缺乏引起的,通常表现为系统性红斑狼疮和带囊生物体感染的特征。由于因子 B、因子 D 和调理素缺乏引起的替代途径缺陷可能表现为对奈瑟菌感染的易感性增加。凝集素途径缺陷,包括甘露糖结合蛋白相关丝氨酸蛋白酶 2 (MASP2) 和 ficolin 3,可能无症状或导致化脓性感染和自身免疫。补体蛋白 C3 是所有途径的共同蛋白,其缺乏使患者易患严重频繁的感染和肾小球肾炎。调节替代途径的因子 H 和因子 I 的缺乏可能导致溶血性尿毒综合征。末端途径缺陷(即 C5、C6、C7、C8 和 C9)导致播散性奈瑟菌感染。补体缺陷的诊断包括功能检测(即总补体活性 [CH50]、替代补体途径活性 [AH50]、酶联免疫吸附试验 [ELISA])进行筛选,然后通过免疫测定测量个体补体因子。补体缺陷的管理需要采用综合和个体化的方法,特别注意针对带囊细菌的疫苗接种、考虑预防性抗生素、治疗并存的自身免疫以及密切监测。